TwinBeech Capital’s Denali Therapeutics DNLI Stock Holding History

TwinBeech Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,000	Closed	-$442K	–	448
2026 Q1	$442K	Buy	+23,000	New	+$458K	0.05%	378
2025 Q3	–	Sell	-210,370	Closed	-$2.94M	–	622
2025 Q2	$2.94M	Buy	210,370 +138,348	+192%	+$1.95M	0.07%	269
2025 Q1	$979K	Sell	72,022 -182,564	-72%	-$3.5M	0.02%	487
2024 Q4	$5.19M	Buy	+254,586	New	+$6.52M	0.09%	218
2024 Q2	–	Sell	-177,364	Closed	-$3.64M	–	598
2024 Q1	$3.64M	Buy	177,364 +136,784	+337%	+$2.57M	0.08%	258
2023 Q4	$871K	Buy	+40,580	New	+$804K	0.01%	503
2023 Q2	–	Sell	-149,302	Closed	-$3.44M	–	662
2023 Q1	$3.44M	Buy	+149,302	New	+$4.11M	0.07%	299
2022 Q2	–	Sell	-18,046	Closed	-$581K	–	555
2022 Q1	$581K	Buy	+18,046	New	+$621K	0.03%	383

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TwinBeech Capital's DNLI Position: Q2 2026 in Review

TwinBeech Capital sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 23,000 shares — an estimated $442K sold.

TwinBeech Capital first reported a position in DNLI in Q1 2022 and held it in 8 quarters. The position peaked at $5.19M in Q4 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

TwinBeech Capital reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
TwinBeech Capital sold 23,000 Denali Therapeutics shares in Q2 2026, an estimated $442K.
TwinBeech Capital first reported a position in Denali Therapeutics in Q1 2022 and held it in 8 quarters.
TwinBeech Capital's Denali Therapeutics position peaked at $5.19M in Q4 2024.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.